AstraZeneca and Oxford University are set to sideline the ‘lucky mistake’ data which boosted the Phase III results of their COVID-19 vaccine earlier this week, after facing criticism about how the study was performed and doubts about the robustness of the interim data.
AZ Will Sideline ‘Lucky Mistake’ To Secure COVID-19 Vaccine Approval
US Unlikely To Accept Data
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
